Preliminary Analysis of the Effects of Ad26.COV2.S Vaccination on CT Findings and High Intensive Care Admission Rates of COVID-19 Patients

On 27 February 2021, the Food and Drug Administration(FDA) authorized the administration of the adenovirus-based Ad26.COV2-S vaccine (J&J-Janssen) for the prevention of COVID-19, a viral pandemic that, to date, has killed more than 5.5 million people. Performed during the early phase of the COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Negroni, Davide, Carriero, Serena, Passarella, Ilaria, Siani, Agnese, Biondetti, Pierpaolo, Pizzolante, Antonio, Saba, Luca, Guzzardi, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611738/
https://www.ncbi.nlm.nih.gov/pubmed/36287798
http://dx.doi.org/10.3390/tomography8050199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611738/
https://www.ncbi.nlm.nih.gov/pubmed/36287798
http://dx.doi.org/10.3390/tomography8050199

Ejemplares similares